about
Pan-Bcl-2 inhibitor, GX15-070 (obatoclax), decreases human T regulatory lymphocytes while preserving effector T lymphocytes: a rationale for its use in combination immunotherapyEffect of a small molecule BCL-2 inhibitor on immune function and use with a recombinant vaccine.Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines.Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapyThe tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitorsDistinct effects of saracatinib on memory CD8+ T cell differentiation.Inhibition of the angiopoietin/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack.TGF-beta modulates the functionality of tumor-infiltrating CD8+ T cells through effects on TCR signaling and Spred1 expressionChemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death.Combination therapy with a second-generation androgen receptor antagonist and a metastasis vaccine improves survival in a spontaneous prostate cancer model.Effects of conventional therapeutic interventions on the number and function of regulatory T cells.Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer.Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial.Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trialIdentification by digital immunohistochemistry of intratumoral changes of immune infiltrates after vaccine in the absence of modifications of PBMC immune cell subsets.Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy.Identification of tumor associated immune responses against brachyury, a transcription factor and driver of EMT, in chordoma patients receiving a yeast-brachyury vaccine (gi-6301).Tumor vascular normalization as a strategy to potentiate effectiveness of therapeutic vaccines.Flow-cytometry phenotypic assessment of immune cell subsets reflecting function for the identification of breast cancer patients receiving vaccine plus docetaxel with longer progression-free survival.Effects of tyrosine kinase inhibitors alone or in combination with vaccine on tumor-infiltrating myeloid cells.Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death.Digital immunohistochemistry analysis of intratumoral immune infiltrates in prostate cancer patients treated with intraprostatic/systemic PSA-TRICOM vaccine.Adverse events after infusions of cryopreserved hematopoietic stem cells depend on non-mononuclear cells in the infused suspension and patient age.PD-L1 and MHC-I expression in 19 human tumor cell lines and modulation by interferon-gamma treatment.PD-1 and PD-L1 expression on PBMC subsets in normal individuals and cancer patientsTherapeutic cancer vaccines.CD34+ selected haematopoietic stem cell (HSC) not preceded by any immunosuppressive therapy as effective treatment for graft failure
P50
Q34004454-8B6F9132-DBE6-490B-AA61-F4CF6A2BD554Q34074715-51C89F7C-95C6-4C0E-90EC-7F132D597BE0Q34458617-89498242-BF4F-4B8C-9099-2B19103727A2Q35597086-E6DC2806-9ED0-449B-B6A5-968FFBA38773Q35975387-7230A7FE-2ABA-4E35-9C38-627F0EE44B1AQ36043797-CA294ED2-1D9B-48A0-A81D-E676C981A017Q36286833-CC256530-E3C5-4348-859F-8661E002E29DQ36402151-D0F2AAEA-E305-4552-94DE-D0EDE107C247Q36874767-D3E4ED32-9B02-4D55-BDD4-D371341FBBE9Q37324881-E57BE6B8-CF0B-450B-880E-1D45426D3791Q37390970-BB796863-7581-4EF6-BAE8-4B0D73153744Q37732958-3B0446CD-0CBD-4DB0-8C0A-50C657D031D1Q38405627-510D5CF9-8E5F-4893-8C00-537B583D0B74Q38906747-59A7FCE7-762C-4FE8-893B-3CC4635850E9Q40167499-53C644B5-0916-4E0A-A481-44BA1192816FQ42358561-B9E63A7B-1677-4ADE-8316-04F9E5F99FA2Q45804967-8492CD64-1235-4AAB-89ED-9F72393B1797Q45842228-8BBE5E7B-BBE7-4DAC-9A44-CC521A0971EEQ46574327-11197DFA-4ECA-4254-B734-0E5C9013D921Q46574702-9B076A22-B298-4603-B64F-046F669D73A6Q46577708-19AF7D96-0E24-4CE3-A1D0-17B077BAC373Q46579558-7715F244-9E39-4DBB-825F-444D13469C58Q53546156-87A638EE-8FF7-42BA-B4FB-48BA8429DAE7Q55690397-A68D5781-8ECC-4457-88F3-DC215CC767D1Q59400488-16A1CCF6-0D3F-478F-B2EC-012B85034BBCQ64924726-F80EF0BE-D810-4792-9240-C20E834C8DEAQ81308452-6DEF53C7-771A-49A6-8833-A395CF658189
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Benedetto Farsaci
@ast
Benedetto Farsaci
@en
Benedetto Farsaci
@es
Benedetto Farsaci
@nl
Benedetto Farsaci
@sl
type
label
Benedetto Farsaci
@ast
Benedetto Farsaci
@en
Benedetto Farsaci
@es
Benedetto Farsaci
@nl
Benedetto Farsaci
@sl
altLabel
Benny
@en
prefLabel
Benedetto Farsaci
@ast
Benedetto Farsaci
@en
Benedetto Farsaci
@es
Benedetto Farsaci
@nl
Benedetto Farsaci
@sl
P1053
L-9837-2014
P106
P2038
Benedetto_Farsaci
P21
P31
P3829
P496
0000-0001-8275-2561